Hayat Kumbasar Karaosmanoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hayat Kumbasar Karaosmanoglu has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Fehmi Tabak
Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
12 shared publications - Bilgul Mete
Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
8 shared publications - Alper Gunduz
Department of Infectious Diseases and Clinical Microbiology, Başakşehir Çam and Sakura City Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
6 shared publications Ozcan Nazlican
Dumlupinar University Faculty of Medicine Student, Kutahya, Turkey
5 shared publications- Behice Kurtaran
Department of Infectious Diseases and Clinical Microbiology, Acıbadem Adana Hospital, Adana 01130, Türkiye
4 shared publications - Esra Zerdali
Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences Haseki Training and Research Hospital, İstanbul, Türkiye
4 shared publications
Latest Publications
- 9 October 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24, 1-7
Proportion and Characteristics of Primary HIV Infection Among Newly Diagnosed Individuals in Istanbul
Introduction: Early identification of Primary HIV İnfection (PHI) is essential to reduce onward transmission and enable prompt initiation of Antiretroviral Therapy (ART). Despite increasing HIV diagnoses in Türkiye, data on the prevalence and characteristics of PHI remain limited. This study aimed to determine the proportion of PHI among newly diagnosed individuals and to describe and compare the sociodemographic and laboratory characteristics of individuals with PHI and CHI. Materials and Methods: This retrospective observational study included 225 individuals newly diagnosed with HIV at a tertiary-care center in Istanbul between June 2024 and October 2025. PHI was defined as a documented negative HIV test within the preceding six months together with a history of unprotected high-risk exposure within 2–6 weeks prior to diagnosis. Sociodemographic and laboratory characteristics were compared between PHI and Chronic HIV İnfection (CHI) groups using univariate analyses. Receiver Operating Characteristic (ROC) analysis was performed to evaluate the discriminative ability of HIV RNA levels. A multivariable logistic regression analysis was additionally performed to assess adjusted associations with PHI. Results: Twenty-five individuals (11.1%; 95% CI 7.6–15.9%) met the criteria for PHI. The PHI group tended to be younger and predominantly men who have sex with men. Median HIV RNA levels were significantly higher in PHI than in CHI (693,000 vs. 66,150 copies/mL, p < 0.001), and HIV RNA >1,000,000 copies/mL was more frequent (39.1% vs. 3.0%, p < 0.001). ROC analysis demonstrated moderate discrimination (AUC 0.76; 95% CI 0.62–0.89), with high specificity but limited sensitivity. In multivariable logistic regression adjusted for age, university-level education remained associated with PHI (adjusted OR 5.97, 95% CI 1.28–27.74; p = 0.023). Discussion: PHI constituted a substantial proportion of newly diagnosed cases in this study, within the range reported in comparable settings. The observed differences in age and transmission category (predominantly men who have sex with men) may reflect both transmission dynamics and testing patterns. Elevated HIV RNA levels during PHI support its role in increased transmission risk; however, the moderate discriminative performance and limited sensitivity of viral load indicate that it should not be used as a standalone diagnostic marker. These findings highlight the importance of integrating clinical history and exposure risk with laboratory parameters. Conclusion: PHI represents a clinically significant proportion of newly diagnosed HIV cases. Improving early recognition through targeted testing strategies and combined clinical and laboratory assessment may enhance early diagnosis and reduce onward transmission.
- 9 October 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24, 1-7
Proportion and Characteristics of Primary HIV Infection Among Newly Diagnosed Individuals in Istanbul
Introduction: Early identification of Primary HIV İnfection (PHI) is essential to reduce onward transmission and enable prompt initiation of Antiretroviral Therapy (ART). Despite increasing HIV diagnoses in Türkiye, data on the prevalence and characteristics of PHI remain limited. This study aimed to determine the proportion of PHI among newly diagnosed individuals and to describe and compare the sociodemographic and laboratory characteristics of individuals with PHI and CHI. Materials and Methods: This retrospective observational study included 225 individuals newly diagnosed with HIV at a tertiary-care center in Istanbul between June 2024 and October 2025. PHI was defined as a documented negative HIV test within the preceding six months together with a history of unprotected high-risk exposure within 2–6 weeks prior to diagnosis. Sociodemographic and laboratory characteristics were compared between PHI and Chronic HIV İnfection (CHI) groups using univariate analyses. Receiver Operating Characteristic (ROC) analysis was performed to evaluate the discriminative ability of HIV RNA levels. A multivariable logistic regression analysis was additionally performed to assess adjusted associations with PHI. Results: Twenty-five individuals (11.1%; 95% CI 7.6–15.9%) met the criteria for PHI. The PHI group tended to be younger and predominantly men who have sex with men. Median HIV RNA levels were significantly higher in PHI than in CHI (693,000 vs. 66,150 copies/mL, p < 0.001), and HIV RNA >1,000,000 copies/mL was more frequent (39.1% vs. 3.0%, p < 0.001). ROC analysis demonstrated moderate discrimination (AUC 0.76; 95% CI 0.62–0.89), with high specificity but limited sensitivity. In multivariable logistic regression adjusted for age, university-level education remained associated with PHI (adjusted OR 5.97, 95% CI 1.28–27.74; p = 0.023). Discussion: PHI constituted a substantial proportion of newly diagnosed cases in this study, within the range reported in comparable settings. The observed differences in age and transmission category (predominantly men who have sex with men) may reflect both transmission dynamics and testing patterns. Elevated HIV RNA levels during PHI support its role in increased transmission risk; however, the moderate discriminative performance and limited sensitivity of viral load indicate that it should not be used as a standalone diagnostic marker. These findings highlight the importance of integrating clinical history and exposure risk with laboratory parameters. Conclusion: PHI represents a clinically significant proportion of newly diagnosed HIV cases. Improving early recognition through targeted testing strategies and combined clinical and laboratory assessment may enhance early diagnosis and reduce onward transmission.
- 6 May 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24 (4) , 283-289
Isolated Anti-HBc in People Living with HIV: A 20-Year Experience from Istanbul, Turkey
Background: Married Men who have Sex with Men (MSM) constitute a bridge popu-lation for HIV diffusion into low-risk groups, with spousal non-disclosure rates exceeding 60% in China. It will increase the risk of secondary transmission within families. Despite the timely implementation of evidence-based interventions, reducing MTCT rates to below 2% in China, residual pediatric infections persist. Introduction: Isolated anti-HBc positivity, defined by the absence of HBsAg and anti-HBs, may reflect prior exposure to HBV, occult infection, or a false-positive result. This study aimed to assess the prevalence of isolated anti-HBc positivity and its associated factors among PLWH in Istanbul, Turkey. Methods: This retrospective cross-sectional study included adult People Living With HIV (PLWH) who underwent HBV serological testing between January 2000 and December 2019 at a tertiary hospital in Istanbul. Demographic and clinical characteristics were analyzed. Results: Among 386 PLWH, 8.8% (n = 34) had isolated anti-HBc positivity. Compared with HBV-seronegative PLWH (n = 194), these patients were older (48 [IQR 42-54] vs. 42 [35-50] years; p = 0.007), more likely to have BMI ≥ 25 kg/m² (p = 0.025), and to report smoking (p = 0.041), based on available data. Pre-ART HBV DNA testing was available in 13/34 (38.2%) pa-tients with isolated anti-HBc, and all tested samples were HBV DNA–negative. Discussion: Isolated anti-HBc prevalence was 8.8% in PLWH; older age, BMI ≥25 kg/m², and smoking were more common in this group. Although no HBV DNA was detected in the tested subset, limited HBV DNA testing precluded estimation of OBI prevalence in this cohort. Conclusion: Recognition of isolated anti-HBc positivity and occult HBV infection is important for ART selection and patient follow-up. Although isolated anti-HBc positivity was identified in 8.8% of this cohort, more systematic and risk-stratified HBV DNA assessment is needed to better define the true burden of occult HBV infection.
- 6 May 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24 (4) , 283-289
Isolated Anti-HBc in People Living with HIV: A 20-Year Experience from Istanbul, Turkey
Background: Married Men who have Sex with Men (MSM) constitute a bridge popu-lation for HIV diffusion into low-risk groups, with spousal non-disclosure rates exceeding 60% in China. It will increase the risk of secondary transmission within families. Despite the timely implementation of evidence-based interventions, reducing MTCT rates to below 2% in China, residual pediatric infections persist. Introduction: Isolated anti-HBc positivity, defined by the absence of HBsAg and anti-HBs, may reflect prior exposure to HBV, occult infection, or a false-positive result. This study aimed to assess the prevalence of isolated anti-HBc positivity and its associated factors among PLWH in Istanbul, Turkey. Methods: This retrospective cross-sectional study included adult People Living With HIV (PLWH) who underwent HBV serological testing between January 2000 and December 2019 at a tertiary hospital in Istanbul. Demographic and clinical characteristics were analyzed. Results: Among 386 PLWH, 8.8% (n = 34) had isolated anti-HBc positivity. Compared with HBV-seronegative PLWH (n = 194), these patients were older (48 [IQR 42-54] vs. 42 [35-50] years; p = 0.007), more likely to have BMI ≥ 25 kg/m² (p = 0.025), and to report smoking (p = 0.041), based on available data. Pre-ART HBV DNA testing was available in 13/34 (38.2%) pa-tients with isolated anti-HBc, and all tested samples were HBV DNA–negative. Discussion: Isolated anti-HBc prevalence was 8.8% in PLWH; older age, BMI ≥25 kg/m², and smoking were more common in this group. Although no HBV DNA was detected in the tested subset, limited HBV DNA testing precluded estimation of OBI prevalence in this cohort. Conclusion: Recognition of isolated anti-HBc positivity and occult HBV infection is important for ART selection and patient follow-up. Although isolated anti-HBc positivity was identified in 8.8% of this cohort, more systematic and risk-stratified HBV DNA assessment is needed to better define the true burden of occult HBV infection.
- Open Access
- 10 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (6) , 673-681
Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye
Background/Aims: Chronic hepatitis C virus (HCV) infection constitutes a substantial healthcare concern in Türkiye. The clinical application of direct-acting antiviral medications (DAAs) has transformed its management. The goal is to assess the efficacy and safety of DAAs in the real-world setting in Turkish patients with chronic HCV. Materials and Methods: Thirty-seven centers from Türkiye recorded 1807 patients to the database. Patients aged >18 years were enrolled to the study. Their demographics, clinical information, DAAs used, efficacy, and safety information were evaluated. Efficacy and safety results were reported for patients with 12-week post-treatment (SVR12) data. Results: Among the patients, 919 (50.9%) were female with a mean of age 56 Å} 15 years (range:18-97 years) and 238 (13%) were cirrhotic. Liver biopsy was performed in 296 patients. Mean histologic activity index score was 7.68 and fibrosis score was 2.58. Baseline mean viral load was 4.11Å~106 copies/mL. Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. Response at the end of treatment was 99.2% (1454/1465) and SVR12 was 97.8% (1289/1318). The DAAs were generally well tolerated. Ten and 13 patients discontinued therapy because of drug-related and unrelated adverse side effects, respectively. Conclusion: This real-world study demonstrated that DAA treatment for HCV is both safe and highly effective. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients’ characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively. Cite this article as: Gunduz A, .ztoprak N., Sarı ND, et al. Efficacy and safety of direct-acting antivirals in patients with hepatitis Cinfection: nationwide real-life data from Türkiye. Turk J Gastroenterol. Published online April 10, 2026. doi:10.5152/tjg.2026.25287
- 10 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (6) , 673-681
Open AccessEfficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye
Background/Aims: Chronic hepatitis C virus (HCV) infection constitutes a substantial healthcare concern in Türkiye. The clinical application of direct-acting antiviral medications (DAAs) has transformed its management. The goal is to assess the efficacy and safety of DAAs in the real-world setting in Turkish patients with chronic HCV. Materials and Methods: Thirty-seven centers from Türkiye recorded 1807 patients to the database. Patients aged >18 years were enrolled to the study. Their demographics, clinical information, DAAs used, efficacy, and safety information were evaluated. Efficacy and safety results were reported for patients with 12-week post-treatment (SVR12) data. Results: Among the patients, 919 (50.9%) were female with a mean of age 56 Å} 15 years (range:18-97 years) and 238 (13%) were cirrhotic. Liver biopsy was performed in 296 patients. Mean histologic activity index score was 7.68 and fibrosis score was 2.58. Baseline mean viral load was 4.11Å~106 copies/mL. Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. Response at the end of treatment was 99.2% (1454/1465) and SVR12 was 97.8% (1289/1318). The DAAs were generally well tolerated. Ten and 13 patients discontinued therapy because of drug-related and unrelated adverse side effects, respectively. Conclusion: This real-world study demonstrated that DAA treatment for HCV is both safe and highly effective. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients’ characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively. Cite this article as: Gunduz A, .ztoprak N., Sarı ND, et al. Efficacy and safety of direct-acting antivirals in patients with hepatitis Cinfection: nationwide real-life data from Türkiye. Turk J Gastroenterol. Published online April 10, 2026. doi:10.5152/tjg.2026.25287
- Open Access
- 1 January 2026
- Published by Wiley in Health & Social Care in the Community
- Vol. 2026 (1)
Health Literacy Levels and Associated Factors Among People Living With HIV: A Cross‐Sectional Study in a Research Hospital in Türkiye
Background: Health literacy (HL) is the ability to access, understand and utilize information and health services. People living with HIV (PLWH) with high HL have higher adherence to antiretroviral therapy (ART) and better long‐term health outcomes. Since HL has a crucial impact on health outcomes, we conducted the first study in Türkiye to identify factors associated with HL in PLWH. Methods: A questionnaire containing demographic data and the HÜ‐SOY scale to measure HL levels was completed by 244 PLWH who agreed to participate in our study. The achieved sample size was sufficient to detect small‐to‐moderate effect sizes, as supported by power and sensitivity analyses. Regarding adherence to ART, the individuals were asked whether they had not taken ART for two consecutive days or for a total of 30 days in the last year. Results: HL levels were lower in patients with low ART adherence ( p = 0.007). A higher level of HL was observed in individuals whose income levels exceeded their expenses and in those with higher education levels ( p < 0.001). Those who did not want to specify their sexual orientation had lower levels of HL ( p = 0.001). The HL level was higher in the group with higher CD4 count but not statistically significant. In multivariable linear regression analysis, higher educational level and sexual orientation remained independently associated with HL levels. Conclusions: HL levels should be assessed before starting ART, and PLWH with low HL should be considered at high risk for treatment nonadherence. On the other hand, for individuals who do not want to disclose their sexual orientation, interventions that increase their HL levels may be beneficial for them to express themselves freely.
- 1 January 2026
- Published by Wiley in Health & Social Care in the Community
- Vol. 2026 (1)
Open AccessHealth Literacy Levels and Associated Factors Among People Living With HIV: A Cross‐Sectional Study in a Research Hospital in Türkiye
Background: Health literacy (HL) is the ability to access, understand and utilize information and health services. People living with HIV (PLWH) with high HL have higher adherence to antiretroviral therapy (ART) and better long‐term health outcomes. Since HL has a crucial impact on health outcomes, we conducted the first study in Türkiye to identify factors associated with HL in PLWH. Methods: A questionnaire containing demographic data and the HÜ‐SOY scale to measure HL levels was completed by 244 PLWH who agreed to participate in our study. The achieved sample size was sufficient to detect small‐to‐moderate effect sizes, as supported by power and sensitivity analyses. Regarding adherence to ART, the individuals were asked whether they had not taken ART for two consecutive days or for a total of 30 days in the last year. Results: HL levels were lower in patients with low ART adherence ( p = 0.007). A higher level of HL was observed in individuals whose income levels exceeded their expenses and in those with higher education levels ( p < 0.001). Those who did not want to specify their sexual orientation had lower levels of HL ( p = 0.001). The HL level was higher in the group with higher CD4 count but not statistically significant. In multivariable linear regression analysis, higher educational level and sexual orientation remained independently associated with HL levels. Conclusions: HL levels should be assessed before starting ART, and PLWH with low HL should be considered at high risk for treatment nonadherence. On the other hand, for individuals who do not want to disclose their sexual orientation, interventions that increase their HL levels may be beneficial for them to express themselves freely.
- Open Access
- 18 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8164
Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?
Background/Objectives: The accurate evaluation of the fibrosis stage is critical for improving chronic hepatitis B (CHB) management and patient outcomes. This study aimed to compare the diagnostic accuracy of non-invasive fibrosis markers with liver biopsy for detecting significant, advanced fibrosis and cirrhosis. We further investigated the diagnostic performance of non-invasive markers according to HBeAg status to provide further insight into their clinical utility across patient subgroups. Methods: This single-center retrospective study included 536 treatment-naive patients with CHB who underwent liver biopsy. Patients were categorized into four groups according to the fibrosis stage: “no significant fibrosis” (F0–F2), “significant fibrosis” (F3–F6), “advanced fibrosis” (F4–F6), and “cirrhosis” (F5–F6). AAR, AAPRI, APRI, API, FIB-4, GPR, and S–index were compared among these groups. Results: In total, 536 treatment-naïve patients were analyzed (63.2% male; mean age 44.8 ± 12.9 years), of whom 25.4% were HBeAg-positive. API, FIB 4, GPR, and S-Index showed good performance (area under the curve [AUC] ≥ 0.8–0.9) in defining advanced fibrosis (≥F4), AAPRI, AAR, API, and APRI showed good performance ([AUC] < 0.700) in defining cirrhosis. The analysis showed that GPR had the highest AUC for ≥F3 (0.719) and ≥F4 (0.838), while FIB 4 had the highest AUC for cirrhosis (0.865). Conclusions: These findings highlight the value of non-invasive markers as inexpensive and easily applicable methods for clinicians in assessing the stage of liver fibrosis. The integration of these scores into the routine monitoring of chronic hepatitis B patients is expected to expand, enhancing clinical decision-making and reducing the necessity for liver biopsies.
- 18 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8164
Open AccessAssessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?
Background/Objectives: The accurate evaluation of the fibrosis stage is critical for improving chronic hepatitis B (CHB) management and patient outcomes. This study aimed to compare the diagnostic accuracy of non-invasive fibrosis markers with liver biopsy for detecting significant, advanced fibrosis and cirrhosis. We further investigated the diagnostic performance of non-invasive markers according to HBeAg status to provide further insight into their clinical utility across patient subgroups. Methods: This single-center retrospective study included 536 treatment-naive patients with CHB who underwent liver biopsy. Patients were categorized into four groups according to the fibrosis stage: “no significant fibrosis” (F0–F2), “significant fibrosis” (F3–F6), “advanced fibrosis” (F4–F6), and “cirrhosis” (F5–F6). AAR, AAPRI, APRI, API, FIB-4, GPR, and S–index were compared among these groups. Results: In total, 536 treatment-naïve patients were analyzed (63.2% male; mean age 44.8 ± 12.9 years), of whom 25.4% were HBeAg-positive. API, FIB 4, GPR, and S-Index showed good performance (area under the curve [AUC] ≥ 0.8–0.9) in defining advanced fibrosis (≥F4), AAPRI, AAR, API, and APRI showed good performance ([AUC] < 0.700) in defining cirrhosis. The analysis showed that GPR had the highest AUC for ≥F3 (0.719) and ≥F4 (0.838), while FIB 4 had the highest AUC for cirrhosis (0.865). Conclusions: These findings highlight the value of non-invasive markers as inexpensive and easily applicable methods for clinicians in assessing the stage of liver fibrosis. The integration of these scores into the routine monitoring of chronic hepatitis B patients is expected to expand, enhancing clinical decision-making and reducing the necessity for liver biopsies.
- 18 June 2025
- Published by SAGE Publications in International Journal of STD & AIDS
Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection
Background: Hepatitis B (HBV) infection affects 4%–14% of people with HIV infection in Turkey. Tenofovir alafenamide (TAF) is highly effective in treatment of HIV infection. While it is active against HBV, data on the use in HIV-HBV co-infection are limited. Patients and Methods: We analyzed the efficacy of tenofovir disoproxil fumarate (TDF)- and TAF-containing regimens in patients with HIV-HBV co-infection from six centers in Istanbul, Turkey. The results of the cohort of 36 months were presented. Results: 259 patients were enrolled: 146 and 113 were receiving TAF- and TDF-containing regimens respectively. Baseline characteristics were comparable except TAF-containing group was older; had higher CD4 cell count and lower rate of CD4 count ≤200 cells/μL. Baseline HIV-RNA were 8.2 log copies/mL and 6.8 log in TAF- and TDF-containing groups, respectively ( p = .059) and HBV-DNA levels were 8.1 log IU/mL in both groups. Thirty-eight and 39% of the patients were HBeAg-positive. After 36 months, undetectable HBV-DNA was noted in 88% and 87%, and undetectable HIV-RNA in 85% and in 83% of TAF and TDF-containing groups, respectively. The increase in mean CD4 cell was significant in both groups: Δ = 311 cells/μL in TAF- and Δ = 393 cells/μL in TDF-containing groups. Rates of HBeAg loss (63% vs 57%), HBeAg seroconversion (35% vs 29%), HBsAg loss (29% vs 27%), and HBsAg seroconversion (23% vs 16%) were comparable at 36 months of therapy. Conclusion: This real-life study showed that both TAF- and TDF-containing regimens are effective in co-infected patients. The rates of HBsAg loss seemed higher than those in HBV-monoinfected patients.
- 18 June 2025
- Published by SAGE Publications in International Journal of STD & AIDS
Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection
Background: Hepatitis B (HBV) infection affects 4%–14% of people with HIV infection in Turkey. Tenofovir alafenamide (TAF) is highly effective in treatment of HIV infection. While it is active against HBV, data on the use in HIV-HBV co-infection are limited. Patients and Methods: We analyzed the efficacy of tenofovir disoproxil fumarate (TDF)- and TAF-containing regimens in patients with HIV-HBV co-infection from six centers in Istanbul, Turkey. The results of the cohort of 36 months were presented. Results: 259 patients were enrolled: 146 and 113 were receiving TAF- and TDF-containing regimens respectively. Baseline characteristics were comparable except TAF-containing group was older; had higher CD4 cell count and lower rate of CD4 count ≤200 cells/μL. Baseline HIV-RNA were 8.2 log copies/mL and 6.8 log in TAF- and TDF-containing groups, respectively ( p = .059) and HBV-DNA levels were 8.1 log IU/mL in both groups. Thirty-eight and 39% of the patients were HBeAg-positive. After 36 months, undetectable HBV-DNA was noted in 88% and 87%, and undetectable HIV-RNA in 85% and in 83% of TAF and TDF-containing groups, respectively. The increase in mean CD4 cell was significant in both groups: Δ = 311 cells/μL in TAF- and Δ = 393 cells/μL in TDF-containing groups. Rates of HBeAg loss (63% vs 57%), HBeAg seroconversion (35% vs 29%), HBsAg loss (29% vs 27%), and HBsAg seroconversion (23% vs 16%) were comparable at 36 months of therapy. Conclusion: This real-life study showed that both TAF- and TDF-containing regimens are effective in co-infected patients. The rates of HBsAg loss seemed higher than those in HBV-monoinfected patients.
- 19 November 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (3) , 185-194
Mental health service utilization among patients followed up in tertiary HIV/AIDS clinics in Turkey: A need for integrated care
Objectives: Mental health (MH) care for people living with HIV (PLWH) emerges as an important unmet need, yet there are no integrated HIV-MH clinics in Turkey. Our aim is to determine MH service use and its associated factors in PLWH followed up in the HIV/AIDS outpatient clinics in Istanbul/Turkey. Methods: A cross-sectional study was conducted at the HIV/AIDS outpatient clinics of the Infectious Diseases (ID) departments in hospitals affiliated with the ACTHIV-IST Study Group. Structured interviews were performed using questionnaires that covered psychiatric state, medical history, and help-seeking behavior. Results: Out of 172 outpatients, 121 (70.3%) reported MH complaints after infection, and 65.6% felt a need to see MH professionals. Among those, 59% shared their MH distress with the ID team. However, only 20.7% applied to an MH service, and 16.5% received psychiatric treatment. Previous MH diagnoses (AOR = 4.11; 95%CI = 1.26–13.39), sharing the disease with the ID team (AOR = 4.18; 95%CI = 1.24–14.11), and being hospitalized due to HIV (AOR = 6.54; 95%CI = 1.21–35.39) emerged as the predictors of MH service use among those who would like to see an MH professional in logistic regression. Conclusions: Closer contact with the healthcare system may increase the chances of PLWH receiving MH care. Thus, integrating MH services in HIV/AIDS care would help reach more PLWH who are distressed.
- 19 November 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (3) , 185-194
Mental health service utilization among patients followed up in tertiary HIV/AIDS clinics in Turkey: A need for integrated care
Objectives: Mental health (MH) care for people living with HIV (PLWH) emerges as an important unmet need, yet there are no integrated HIV-MH clinics in Turkey. Our aim is to determine MH service use and its associated factors in PLWH followed up in the HIV/AIDS outpatient clinics in Istanbul/Turkey. Methods: A cross-sectional study was conducted at the HIV/AIDS outpatient clinics of the Infectious Diseases (ID) departments in hospitals affiliated with the ACTHIV-IST Study Group. Structured interviews were performed using questionnaires that covered psychiatric state, medical history, and help-seeking behavior. Results: Out of 172 outpatients, 121 (70.3%) reported MH complaints after infection, and 65.6% felt a need to see MH professionals. Among those, 59% shared their MH distress with the ID team. However, only 20.7% applied to an MH service, and 16.5% received psychiatric treatment. Previous MH diagnoses (AOR = 4.11; 95%CI = 1.26–13.39), sharing the disease with the ID team (AOR = 4.18; 95%CI = 1.24–14.11), and being hospitalized due to HIV (AOR = 6.54; 95%CI = 1.21–35.39) emerged as the predictors of MH service use among those who would like to see an MH professional in logistic regression. Conclusions: Closer contact with the healthcare system may increase the chances of PLWH receiving MH care. Thus, integrating MH services in HIV/AIDS care would help reach more PLWH who are distressed.
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 22 (4) , 266-269
Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye
Introduction: Abacavir is among the first-line initial antiretroviral regimens for most patients living with HIV/AIDS (PLWHA). Although well tolerated, it is associated with hypersensitivity reaction (HSR), which is treatment-limiting and potentially life-threatening. HSR was shown to be associated with the class I MHC allele, HLA-B*57:01. In this study, we aimed to evaluate the prevalence of HLA-B*57:01 in PLWHA in Istanbul, Türkiye. Material and Methods: Five HIV treatment centers in Istanbul included all sequential treatment-- naïve, ≥ 18 years adult PLWHA, between December 2017- December 2021. Demographic, clinical, and laboratory data were collected at baseline and during treatment. HLA-B* 57:01 genotyping was determined with PCR-SSP. Results: Eight hundred sixty-seven PLWHA were included (male:91%, mean age 39.6±11.1 years). 1.6% of patients were found to be HLA-B*57:01 positive. Among HLA-B*57:01 positive patients, 4 were initially given abacavir-containing treatment; they were switched to non-abacavir treatment upon the allele found to be positive. Conclusion: Although previous studies reported the HLA-B*57:01 prevalence of PLWHA in Türkiye as 3-3.6%, we have found the prevalence to be 1.6%. The current study includes higher numbers of patients than the previous studies. Furthermore, patients from all over the country apply to the centers in Istanbul; compared to the other studies, which involve patients limited to the relevant regions, it can be assumed that the number in our cohort is more representative of the country. In conclusion, the prevalence of the HLA-B*57:01 allele in PLWHA in this study is relatively low. With evident benefit in preventing abacavir HSR, HLA-B*57:01 should be screened in planning antiretroviral therapy.
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 22 (4) , 266-269
Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye
Introduction: Abacavir is among the first-line initial antiretroviral regimens for most patients living with HIV/AIDS (PLWHA). Although well tolerated, it is associated with hypersensitivity reaction (HSR), which is treatment-limiting and potentially life-threatening. HSR was shown to be associated with the class I MHC allele, HLA-B*57:01. In this study, we aimed to evaluate the prevalence of HLA-B*57:01 in PLWHA in Istanbul, Türkiye. Material and Methods: Five HIV treatment centers in Istanbul included all sequential treatment-- naïve, ≥ 18 years adult PLWHA, between December 2017- December 2021. Demographic, clinical, and laboratory data were collected at baseline and during treatment. HLA-B* 57:01 genotyping was determined with PCR-SSP. Results: Eight hundred sixty-seven PLWHA were included (male:91%, mean age 39.6±11.1 years). 1.6% of patients were found to be HLA-B*57:01 positive. Among HLA-B*57:01 positive patients, 4 were initially given abacavir-containing treatment; they were switched to non-abacavir treatment upon the allele found to be positive. Conclusion: Although previous studies reported the HLA-B*57:01 prevalence of PLWHA in Türkiye as 3-3.6%, we have found the prevalence to be 1.6%. The current study includes higher numbers of patients than the previous studies. Furthermore, patients from all over the country apply to the centers in Istanbul; compared to the other studies, which involve patients limited to the relevant regions, it can be assumed that the number in our cohort is more representative of the country. In conclusion, the prevalence of the HLA-B*57:01 allele in PLWHA in this study is relatively low. With evident benefit in preventing abacavir HSR, HLA-B*57:01 should be screened in planning antiretroviral therapy.
- Open Access
- 30 September 2023
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 36 (3) , 154-157
After the HIV/AIDS Congress 2022 (24-27 November 2022, Antalya): Gains, Challenges and Recommendations for the Future Response to HIV Infection in Türkiye
The National HIV/AIDS Congress, organized every year by the Turkey HIV/AIDS Platform, which was formed by the five physician associations operating in the field of HIV infection in Turkey, was held in Antalya on 24-27 November 2022. This congress, AIDS and Sexually Transmitted Diseases Association (AIDS and STD Association), HIV/AIDS Prevention and Education Association (HAKED), HIV Infection Association (HIVEND), Turkish Infectious Diseases and Clinical Microbiology Specialist Association (EKMUD) and Turkish Clinical Microbiology and Infectious Diseases (KLİMİK) Association. In addition, the Red Ribbon Association, Positive-iz Association, and Positive Living Association, three subject associations operating in the field, contributed. This report aims to summarize the data presented by the health professionals, health authorities, and non-governmental organizations working at the forefront of the response to the HIV/AIDS epidemic in our country, their shares and discussions during the congress, and to determine the needs by analyzing the current situation in our country in the light of these.
- 30 September 2023
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 36 (3) , 154-157
Open AccessAfter the HIV/AIDS Congress 2022 (24-27 November 2022, Antalya): Gains, Challenges and Recommendations for the Future Response to HIV Infection in Türkiye
The National HIV/AIDS Congress, organized every year by the Turkey HIV/AIDS Platform, which was formed by the five physician associations operating in the field of HIV infection in Turkey, was held in Antalya on 24-27 November 2022. This congress, AIDS and Sexually Transmitted Diseases Association (AIDS and STD Association), HIV/AIDS Prevention and Education Association (HAKED), HIV Infection Association (HIVEND), Turkish Infectious Diseases and Clinical Microbiology Specialist Association (EKMUD) and Turkish Clinical Microbiology and Infectious Diseases (KLİMİK) Association. In addition, the Red Ribbon Association, Positive-iz Association, and Positive Living Association, three subject associations operating in the field, contributed. This report aims to summarize the data presented by the health professionals, health authorities, and non-governmental organizations working at the forefront of the response to the HIV/AIDS epidemic in our country, their shares and discussions during the congress, and to determine the needs by analyzing the current situation in our country in the light of these.
- Open Access
- 13 September 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (5) , 367-372
Factors Influencing HIV Infection in Children Born to HIV-Infected Mothers in Turkey
Background: Human immunodeficiency virus (HIV) is still a challenge for children. About 15 to 45% of the HIV positive pregnant women can transmit the virus to their children during pregnancy, delivery and/or breastfeeding. The risk of transmission can be decreased my several measures.Aims: To identify factors associated with HIV infection in children born to HIV-infected mothers.Study Design: A multi-center retrospective cohort study.Methods: A ten-year retrospective cohort study in five dedicated HIV centers was conducted. The 325 women in our cohort were between the ages of 18 and 45. During the study period, 44 (13.5%) of thesewomen gave birth and 51 babies were born. Of the 51 infants, 7 (13.7%) were HIV/AIDS positive.Results: Among the factors studied, breastfeeding, having a HIV positive sibling and being on antiretroviral treatment during pregnancy and detectable HIV-RNA during delivery were found statistically significant. A multivariable logistic regression analysis showed that being on antiretroviral treatment during pregnancy is the most important predictor of mother-to-child transmission. Conclusion: Mother-to-child transmission appears to be an important route of HIV transmission in Turkey. Lack of antiretroviral treatment during pregnancy appears to be a key factor in transmission.
- 13 September 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (5) , 367-372
Open AccessFactors Influencing HIV Infection in Children Born to HIV-Infected Mothers in Turkey
Background: Human immunodeficiency virus (HIV) is still a challenge for children. About 15 to 45% of the HIV positive pregnant women can transmit the virus to their children during pregnancy, delivery and/or breastfeeding. The risk of transmission can be decreased my several measures.Aims: To identify factors associated with HIV infection in children born to HIV-infected mothers.Study Design: A multi-center retrospective cohort study.Methods: A ten-year retrospective cohort study in five dedicated HIV centers was conducted. The 325 women in our cohort were between the ages of 18 and 45. During the study period, 44 (13.5%) of thesewomen gave birth and 51 babies were born. Of the 51 infants, 7 (13.7%) were HIV/AIDS positive.Results: Among the factors studied, breastfeeding, having a HIV positive sibling and being on antiretroviral treatment during pregnancy and detectable HIV-RNA during delivery were found statistically significant. A multivariable logistic regression analysis showed that being on antiretroviral treatment during pregnancy is the most important predictor of mother-to-child transmission. Conclusion: Mother-to-child transmission appears to be an important route of HIV transmission in Turkey. Lack of antiretroviral treatment during pregnancy appears to be a key factor in transmission.